Capital City, Xicheng District Drug Administration Bureau.
On this day, a few people hurried to the door. The fat man leading them was none other than Mr. Swansea, the president of Sanofi China.
He had a furrowed brow and a serious expression, followed closely by several staff members from the quality control department.
Generally speaking, when the Drug Administration Bureau meets with pharmaceutical companies, it does not require the highest-ranking official like him to attend; it only needs to send quality inspectors.
However, the Drug Administration Bureau's announcement came very suddenly, with an unusually stern tone, and without prior communication, indicating a very serious situation. Therefore, Mr. Swansea had no choice but to personally attend the meeting.
He was afraid that a mishandling of the situation would cause the company significant losses again.
The company is in such a state that it really can't withstand any more setbacks.
The group was led to an empty conference room and waited anxiously.
Soon, several staff members from the Drug Supervision and Administration Department walked in.
When Mr. Swansea first saw the middle-aged man with glasses walking at the front, his heart skipped a beat, and he knew something was wrong.
He had already recognized the other party; it was a powerful deputy director of the Drug Administration Bureau, who was in charge of drug safety issues and had a great reputation in the industry, making him very difficult to deal with.
He handled several serious safety incidents involving domestic pharmaceutical companies, and he was also the one who conducted the talks regarding Johnson & Johnson's Recallgate incident.
Generally, when he personally intervenes in a meeting, it indicates that the problem is serious and the authorities are taking it very seriously.
This is no longer a typical recall issue that a few State Administration of Radio and Television staff could handle.
Mr. Swansea forced a warm smile, strode forward, and extended his hand, saying, "Director Li, it's a pleasure to meet you. I'm Mr. Swansea from Sanofi. It's a pleasure to meet you."
Director Li nodded expressionlessly, without speaking or extending a hand, and sat down directly opposite.
Mr. Swansea awkwardly withdrew his hand, touched his nose, and sat back down.
He took a stack of documents out of his briefcase and handed them over.
"Hello, regarding these three Irbesartan drugs sold in China, we have prepared sufficient supporting documents, including several qualified quality inspection reports. Moreover, the manufacturers are different from those in other countries, which is sufficient to prove that the drugs on the market do not have any carcinogenic impurities. Please take a look."
Director Li made no move, but the staff member next to him took the document, flipped through it, and frowned.
"These are all your own internal documents and don't prove anything."
"Since your other factories have had problems, it means that you have issues with poor production conditions and lax management. Usually, such serious product quality control failures are not isolated incidents. There are likely major hidden dangers in the manufacturing process and raw materials. In this sense, your other factories are not safe either."
"Besides, even if the production plants are different, the raw materials and excipients used are the same, isn't there still a risk? So your report is really not convincing."
"Do you have any other supporting documents? For example, third-party testing reports? A summary of the problematic drug batches? The impact of carcinogenic impurities in the drug on its efficacy, and the potential consequences for patients?"
Mr. Swansea was speechless for a moment when faced with this barrage of questions.
He racked his brains for a few excuses, carefully considered his words, and was about to give his reply.
Director Li suddenly spoke up, "Alright, put away all your excuses."
He waved his hand, and another staff member next to him took out a few thin sheets of paper and placed them on the table.
"You may have misunderstood something. We didn't call you here to defend yourself, but to tell you a fact."
"This is the result of a random sampling test conducted by our testing center on three Irbesartan drugs."
"You can take a look at these data. One of them does contain trace amounts of Nitrosamines. You should understand that this is a strong carcinogen without me having to remind you."
Mr. Swansea was completely stunned, as if struck by lightning.
After a while, he picked up the test report and began to read it carefully.
As he looked at them, his hands began to tremble uncontrollably, shaking like leaves in the wind, and he could barely hold the few thin pages.
He let the document slip from his fingers, his face filled with disbelief, muttering, "How could this be?"
Nitrosamines are recognized as potent carcinogens. Scientists first began to pay attention to them in the 1960s when experimental animals suffered liver failure after being fed fishmeal with high levels of Sodium Nitrite. This prompted people to start studying them.
Sodium Nitrite combines with amines to form Nitrosamines, and Sanofi's Irbesartan contains N-nitrosodimethylamine, a potent carcinogen that can cause liver failure.
Liver failure is just one manifestation of its toxicity; more often, it can cause other diseases such as lung cancer.
Generally speaking, the content of carcinogenic impurities in Antihypertensive Drug is very low, and most of them come from excipients, not from the raw materials.
As long as the raw materials are strictly controlled and improvements are made to the manufacturing process, and strict supervision is implemented, such problems can be completely avoided and are not considered particularly serious safety incidents.
However, patients often have to take Antihypertensive Drug for more than ten or even twenty or thirty years. Even if the dosage is extremely low, the consequences of such long-term use are unpredictable.
N-nitrosamines are also found in cigarettes, and smoking is one of the important pathogenic factors for lung cancer.
The dosage of Antihypertensive Drug is certainly not that high, and cigarettes contain many carcinogens, not just N-nitrosamines.
However, there are significant differences in physical constitution among individuals. Some people can develop lung cancer from secondhand smoke, while some heavy smokers can live healthily to the age of 90. The probability of Cancer Cells mutation is often very difficult to predict.
Therefore, completely eliminating such a dangerous carcinogen is the safest and most reliable measure.
Mr. Swansea was now completely speechless.
He lowered his head, his attitude extremely sincere, and said, "This is indeed our mistake, but I need to report this to headquarters first before..."
Director Li immediately interrupted him, "You only have one choice now."
"Either recall immediately, or ban your company's drugs from sale in China."
"Choose one of the two."
His voice was unusually cold, like a judge high above delivering a final verdict on Sanofi's crimes.
Mr. Swansea broke out in a cold sweat. He knew he couldn't fool them anymore, and delaying tactics wouldn't work.
If recalling the problematic drugs would cause the company huge losses, then being banned from sale would be an unbearable burden.
I had no choice but to grit my teeth and agree.
He nodded vigorously, agreeing immediately.
"Okay, okay, we will immediately recall all the problematic medications, offer a sincere apology, and compensate the patients who have suffered losses."
At this moment, Director Li finally showed a rare smile and nodded, seemingly satisfied with his tactful manner.
Since a result had already been reached, the meeting ended quickly.
Mr. Swansea walked out of the Drug Administration Bureau building looking dejected, followed by a group of subordinates who were just there to observe.
A strong sense of regret flashed through his mind.
If I had known it would turn out like this, I should have proactively recalled them when the incident occurred; maybe I could have earned a good reputation for admitting my mistakes and correcting them.
Now, not only will they be publicly criticized by the Drug Administration Bureau, but the issue of Antihypertensive Drug causing cancer has also been thoroughly investigated.
After all, proactive recalls can be seen as being prepared for unforeseen circumstances, taking drug safety seriously, being responsible to patients, and treating everyone equally.
However, being ordered to recall the product by a notice from the Drug Administration Bureau is a different matter altogether.
Regardless of whether there are any problems or not, these three Antihypertensive Drug have completely ruined their reputation.
The lost market share can never be recovered.
Sanofi, like the Stick Country company Samsung Group, will be forever branded with shame.